Janssen secures a ‘yes, but’ MSAC response as Gilead strengthens its lead with an important recommendation and expanded people focus.
Ahead of IWD24, BioMarin MD and author of Advance Australia Fairly, Dr Kathryn Evans, questions pharma’s pace of change in gender equality.
He’s a well-known face in pharma having worked at Merck, Shire and Sanofi, and now he’s notched up an early win as a first-time GM.
Collaborating with Access partners on a new work-sharing priority pathway for advanced medicinal therapy products (ATMPs).
The PBAC and MSAC chairs are fast approaching their end dates with no successor named as the HTA Review also runs short on time.
What are the top 10 trends influencing health purchasing policies over the coming financial year? A new report reveals all.
Ozempic or Wegovy? Mounjaro or Zepound? With some therapies now getting two names, what do they actually mean?
What Australians think about your brand & industry revealed and unpacked at this exclusive MedNews event.
We look at two of the biggest HTA options on the table to see where they came from, and what they are likely to mean for Australia.
MedNews Live Updates will be back soon.